2- chloro- N(6)- (3- iodobenzyl)adenosine- 5'- N- methyluronamide

structure given in first source

Also Known As:

2-Cl-IB-MECA; 2-chloro-N(6)-(3-iodobenzyl)-9-(5-(methylcarbamoyl)-beta-D-ribofuranosyl)adenine; 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide; C-IBzA-MU; CF102 compound

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: 6
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: 6
  - Ribonucleosides: 49
    - Adenosine: 12431
      - 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: 6

Experts

1.	Feng, Xiao: 2 articles (03/2015 - 01/2014)
2.	He, Yanting: 2 articles (03/2015 - 01/2014)
3.	Qiu, Yumei: 2 articles (03/2015 - 01/2014)
4.	Ren, Tianhua: 2 articles (03/2015 - 01/2014)
5.	Tian, Ting: 2 articles (03/2015 - 01/2014)
6.	Wu, Weiyun: 2 articles (03/2015 - 01/2014)
7.	Ye, Shicai: 2 articles (03/2015 - 01/2014)
8.	Yu, Caiyuan: 2 articles (03/2015 - 01/2014)
9.	Zhou, Yu: 2 articles (03/2015 - 01/2014)
10.	Maddock, Helen L: 2 articles (02/2014 - 10/2002)

Related Diseases

1.	Neuroinflammatory Diseases 09/30/2020 - "This work demonstrates that 2-Cl-IB-MECA, the selective agonist of A3R, is able to hinder microglia reactivity, suggesting that A3R agonists could afford protection against glaucomatous degeneration through the control of neuroinflammation."
2.	Colitis 03/12/2015 - "However, there are no studies on the effect of 2-Cl-IB-MECA and the molecular mechanism of action of A3AR in murine colitis models in vivo. " 03/12/2015 - "The interaction between 2-CL-IB-MECA and A3AR in a murine colitis model and the signaling pathways associated with this interaction remain unclear. "
3.	Infarction (Infarctions) 10/01/2002 - "In isolated hearts, 2-Cl-IB-MECA significantly limited infarct size (44.2 +/- 2.7% in control vs. 21.9 +/- 2.4% at 1 nM and 35.8 +/- 3.3% at 0.1 nM, P < 0.05). " 02/01/2014 - "2-CL-IB-MECA significantly reduced infarct size compared to non-treated controls, where co-administration with either of the kinase inhibitors abolished the infarct sparing effects. "
4.	Necrosis 02/01/2014 - "2-CL-IB-MECA when administered throughout reoxygenation significantly reduced apoptosis, necrosis, cleaved-caspase 3 activity and increased p-BAD (Ser-112) and p-BAD (Ser-136) activity in myocytes subjected to hypoxia/reoxygenation injury. "
5.	Inflammation (Inflammations) 01/01/2014 - "To investigate the expression of adenosine A3 receptor (A3AR) in human colonic epithelial cells and the effects of A3AR activation on tumor necrosis factor alpha (TNF-α-) induced inflammation in order to determine its mechanism of action in human colonic epithelial cells, human colonic epithelial cells (HT-29 cells) were treated with different concentrations of 2-Cl-IB-MECA prior to TNF-α stimulation, followed by analysis of NF-κB signaling pathway activation and downstream IL-8 and IL-1β production. "

Related Drugs and Biologics

1.	Caspase 3 (Caspase-3)
2.	Adenosine A3 Receptor
3.	Interleukin-8 (Interleukin 8)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Phosphotransferases (Kinase)
6.	Histamine (Histamine Dihydrochloride)

Related Therapies and Procedures

1.	Intravenous Administration